The Effects of K-111, a New Insulin-sensitizer, on Metabolic Syndrome in Obese Prediabetic Rhesus Monkeys

Hormone and Metabolic Research

Volumn 35, Issue 10, 2003, Pages 617-624

  Bodkin, N L ^a   Pill, J ^b   Meyer, K ^b   Hansen, B C ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b ROCHE DIAGNOSTICS GMBH   (Germany)

Author keywords

BM 17.0744; Calorie restriction mimetic; Dyslipidemia; Hyperinsulinemia; Insulin resistance syndrome; K 111; Metabolic syndrome X; Peroxisome proliferator activated receptor ; Thiazolidinedione; Type 2 diabetes mellitus

Indexed keywords

2,2 DICHLORO 12 (4 CHLOROPHENYL)DODECANOIC ACID; DECANOIC ACID DERIVATIVE; GLUCOSE; INSULIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE MEASUREMENT; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; GLUCOSE TRANSPORT; HORMONE ACTION; HORMONE DETERMINATION; HYPERINSULINEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; METABOLIC SYNDROME X; NONHUMAN; OBESITY; PRIORITY JOURNAL; RHESUS MONKEY; WEIGHT REDUCTION;

ANIMALS; BLOOD GLUCOSE; BLOOD PRESSURE; CHOLESTEROL, HDL; DIABETES MELLITUS, TYPE 2; FASTING; GLUCOSE CLAMP TECHNIQUE; GLYCOSURIA; INSULIN; INSULIN RESISTANCE; LAURIC ACIDS; MACACA MULATTA; MALE; METABOLIC SYNDROME X; OBESITY; PREDIABETIC STATE; TRIGLYCERIDES; WEIGHT LOSS;

ANIMALIA; MACACA MULATTA; PRIMATES;

EID: 0344586732     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-43510     Document Type: Article

References (61)

1. Himsworth HP. Diabetes mellitus: Its differentiation into insulin sensitive and insulin insensitive types. Lancet 1936; 1: 127-130
2. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: A method for quantifying insulin secretion and resistance. Am J Physiol 1979; 237: E214-E223
3. DeFronzo R, Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14: 173-194
4. Lillioja S et al. Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians. N Engl J Med, 1993; 329 (27): 1988-92
5. Kahn CR. Banting Lecture. Insulin action, diabetogenes, and the cause of type II diabetes. Diabetes 1994; 43(8): 1066-1084
6. Beck-Nielsen H. General characteristics of the insulin resistance syndrome: prevalence and heritability. European Group for the Study of Insulin Resistance (EGIR). Drugs 1999; 58 (Suppl 1): 7-10; discussion 75-82
7. Vague J. The degree of masculine differentation of obesities: a factor determining predisposition to diabetes, atherosclerosis, gout, and uric calculous disease. Am J Clin Nutr 1956; 4: 20-34
8. Reaven G. Banting lecture 1988: Role of insulin resistance in human disease. Diabetes 1988; 30: 1595-1607
9. Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 1996; 45 (12): 1661-1669
10. Day C. Thiazolidinediones: a new class of antidiabetic drugs. Diabet Med 1999; 16(3): 179-192
11. Lehmann JM et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR α). J Biol Chem 1995; 270 (22): 12953-12956
12. Meyer K et al. Species differences in induction of hepatic enzymes by BM 17.0744, an activator of peroxisome proliferator-activated receptor alpha (PPARa). Arch Toxicol 1999; 73: 440-450
13. Pill J, Meyer K. Reduction of risk factors for cardiovascular complications by BM 17.0744. Cardiovasc Drug Rev 1999; 17: 246-264
14. Meyer K et al. ω-Substituted alkyl carboxylic acids as antidiabtetic and lipid-loweringagents. Eur J Med Chem 1998; 33: 775-778
15. Wurch T et al. Pharmacological analysis of wild-type alpha, gamma and delta subtypes of the human peroxisome proliferator-activated receptor. Naunyn Schmiedebergs Arch Pharmacol, 2002; 365 (2): 133-140
16. Pill J, Kuehnle HF. BM 17.0744: a structurally new antidiabetic compound with insulin-sensitizing and lipid-lowering activity. Metabolism 1999; 48 (1): 34-40
17. Hansen BC, Bodkin NL. Heterogeneity of insulin responses: phases in the continuum leading to non-insulin-dependent diabetes mellitus. Diabetologia 1986; 29: 713-719
18. Bodkin NL, Metzger BL, Hansen BC. Hepatic glucose production and insulin sensitivity preceding diabetes in monkeys. Am J Physiol 1989; 256 (Endocrinol Metab): E676-E681
19. Hansen B, Bodkin NL. β-cell hyperresponsiveness: earliest event in development of diabetes in monkeys. Am J Physiol 1990; 259 (Regulatory Integrative Comp Physiol 28): R612-R617
20. Hannah JS et al. Changes in lipoprotein concentrations during the development of noninsulin dependent diabetes mellitus in obese rhesus monkeys (Macaca mulatta). J Clin Endocrinol Metab 1991; 72: 1067-1072
21. Bodkin NL et al. Insulin-like growth factor-I in non-insulin-dependent diabetic monkeys: Basal plasma concentrations and metabolic effects of exogenously administered biosynthetic hormone. Metabolism 1991; 40: 1131-1137
22. Bodkin NL, Hansen BC. Antihypertensive effects of captopril without adverse effects on glucose tolerance in hyperinsulinemic rhesus monkeys. J Med Primatol 1995; 24: 1-6
23. Ortmeyer HK et al. In vivo D-chiroinositol activates skeletal muscle glycogen synthase and inactivates glycogen phosphorylase in rhesus monkeys. J Nutr Biochem 1995; 6: 499-503
24. Ortmeyer HK, Larner J, Hansen BC Effects of D-chiroinositol added to a meal on plasma glucose and insulin in hyperinsulinemic rhesus monkeys. Obes Res 1995; 3 (4): 605S-608S
25. Young AA et al. Glucose-lowering and insulin-sensitizing actions of Exendin-4: Studies in obese (ob/ob, db/db) diabetic mice, diabetic Fatty Zucker rats and diabetic monkeys (Macaca mulatta ). Diabetes 1999; 48: 1026-1034
26. Hannah JS et al. Effects of acipimox on the metabolism of free fatty acids and VLDL triglyceride. Acta Diabetologia 1995; 32: 279-293
27. Winegar DA et al. Effects of fenofibrate on lipid parameters in obese rhesus monkeys. J Lipid Res 2001; 42 (10): 1543-1551
28. Kemnitz JW et al. Pioglitazone increases insulin sensitivity, reduces blood glucose, insulin, and lipid levels, and lowers blood pressure, in obese, insulin-resistant rhesus monkeys. Diabetes 1994; 43 (2): 204-211
29. Ortmeyer HK et al. A thiazolidinedione improves in vivo insulin action on skeletal muscle glycogen synthase in insulin-resistant monkeys. Int J Exp Diabetes Res 2000; 1 (3): 195-202
30. National Research Council Commission on Life Sciences - Institute of Laboratory Animal Resources, Guide for the care and use of laboratory animals. Washington, D.C.: National Academy Press, 1996
31. Hansen BC et al. Neural influences on oscillations in basal plasma levels of insulin in monkeys. Am J Physiol (Endocrinol Metab 1) 1981; 240: E5-E11
32. Hansen BC et al. Rapid oscillations of plasma insulin, glucagon, and glucose in obese and normal weight humans. J Clin Endo Metab 1982; 54: 785-792
33. Ortmeyer HK, Bodkin NL, Hansen BC. Adipose tissue glycogen synthase activation by in vivo insulin in spontaneously insulin-resistant and Type 2 (non-insulin-dependent) diabetic rhesus monkeys. Diabetologia 1993; 36: 200-206
34. Ortmeyer HK, Bodkin NL, Hansen BC. Insulin-mediated glycogen synthase activity in muscle of spontaneously insulin-resistant and diabetic rhesus monkeys. Am J Physiol 1993; 265 (Regulatory Integrative Comp Physiol 34): R552-R558
35. Bogardus C et al. Relationship between degree of obesity and in vivo insulin action in man. Am J Physiol 1985; 248 (Endocrinol Metab 11): E286-E291
36. Bogardus C et al. Correlation between muscle glycogen synthase activity and in vivo insulin action in man. J Clin Invest 1984; 73: 1185-1190
37. Chen Y-D, Reaven G. Insulin resistance and atherosclerosis. Diabetes Reviews 1997; 5: 331-342
38. Beck-Nielsen H, Groop LC. Metabolic and genetic characterization of prediabetic states. Sequence of events leading to non-insulin-dependent diabetes mellitus. J Clin Invest 1994; 94 (5): 1714-1721
39. Taskinen MR. Insulin resistance and lipoprotein metabolism. Curr Opin Lipidol 1995; 6(3): 153-160
40. Kohrt WM et al. Insulin resistance in aging is related to abdominal obesity. Diabetes 1993; 42: 273-281
41. Ortmeyer HK et al. In vivo D-chiroinositol activates skeletal muscle glycogen synthase and inactivates glycogen phosphorylase in normal and diabetic rhesus monkeys. Diabetes 1992; 41: 106A
42. Oliver WJ et al. A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proceedings of the National Academy of Sciences of the United States of America 2001; 98: 5306-5311
43. Shimaya A et al. The novel hypoglycemic agent YM440 normalizes hyperglycemia without changing body fat weight in diabetic db/db mice. Metabolism 2000; 49: 411-417
44. Hansen BC, Bodkin NL. Primary prevention of diabetes mellitus by prevention of obesity in monkeys. Diabetes 1993; 42: 1809-1814
45. Bodkin NL, Ortmeyer HK, Hansen BC. Long-term dietary restriction in older-aged rhesus monkeys: effects on insulin resistance. J Gerontol A: Biol Sci Med Sci 1995; 50: B142-B147
46. Maegawa H et al. Thiazolidine derivatives ameliorate high glucose-induced insulin resistance via the normalization of protein-tyrosine phosphatase activities. J Biol Chem 1995; 270 (13): 7724-7730
47. Kobayashi M et al. Pioglitazone increases insulin sensitivity by activating insulin receptor kinase. Diabetes 1992; 41 (4): 476-483
48. Ribon V et al. Thiazolidinediones and insulin resistance: peroxisome proliferatoractivated receptor gamma activation stimulates expression of the CAP gene. Proc Natl Acad Sci USA 1998; 95 (25): 14751-14756
49. Ciaraldi TP et al. Regulation of glucose transport in cultured muscle cells by novel hypoglycemic agents. Metabolism 1995; 44 (8): 976-981
50. Fujiwara T et al. Suppression of hepatic gluconeogenesis in long-term Troglitazone treated diabetic KK and C57BL/KsJ-db/db mice. Metabolism 1995; 44: 486-490
51. Juge-Aubry CE et al. Regulation of the transcriptional activity of the peroxisome proliferator-activated receptor alpha by phosphorylation of a ligand-independent trans-activating domain. J Biol Chem 1999; 274 (15): 10505-10510
52. Torra IP, Gervois P, Staels B. Peroxisome proliferator-activated receptor alpha in metabolic disease, inflammation, atherosclerosis and aging. Curr Opin Lipidol 1999; 10: 151-159
53. Guerre-Millo M et al. Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem 2000; 275 (22): 16638-16642
54. Ye JM et al. Peroxisome proliferator-activated receptor (PPAR)-alpha activation lowers muscle lipids and improves insulin sensitivity in high fat-fed rats: comparison with PPAR-gamma activation. Diabetes 2001; 50 (2): 411-417
55. Alberti K, Zimmett P. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1. Diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabetic Medicine 1998; 15: 539-553
56. Shibuya A et al. An autopsy case of troglitazone-induced fulminant hepatitis [see comments]. Diabetes Care 1998; 21 (12): 2140-2143
57. Watkins PB, Whitcomb RW. Hepatic dysfunction associated with troglitazone [letter; comment]. N Engl J Med 1998; 338 (13): 916-917
58. Kemnitz JW et al. Dietary restriction increases insulin sensitivity and lowers blood glucose in rhesus monkeys. Am J Physiol 1994; 266: E540-E547
59. Lane MA et al. Diet restriction in rhesus monkeys lowers fasting and glucose-stimulated glucoregulatory end points. Am J Physiol 1995; 268: E941-E948
60. Ortmeyer HK, Bodkin NL, Hansen BC. Chronic caloric restriction alters glycogen metabolism in rhesus monkeys. Obes Res 1994; 2: 549-555
61. Cefalu WT et al. A study of caloric restriction and cardiovascular aging in cynomolgus monkeys (Macaca fascicularis): a potential model for aging research. J Gerontol A Biol Sci Med Sci 1997; 52 (1): B10-B19